|
Interim safety and efficacy data of [212Pb]VMT-a-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs). |
|
|
Stock and Other Ownership Interests - Clarity Pharmaceuticals |
Honoraria - Abdera Thereapeutics; Bristol-Myers Squibb; Jubilant DraxImage; Molecular Targeting Technologies; Radiopharm Theranostics; Seno Medical; Siemens Healthineers; Voximetry |
Consulting or Advisory Role - clarity pharmaceuticals |
Research Funding - Actinium Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Fusion Pharmaceuticals (Inst); perspective/viewpoint pharmaceuticals (Inst); RayzeBio (Inst); Siemens Healthineers (Inst); white rabbit AI (Inst) |
Travel, Accommodations, Expenses - Actinium Pharmaceuticals; Siemens Healthineers |
Other Relationship - society of nuclear medicine |
|
|
Research Funding - RayzeBio |
|
|
Research Funding - Perspective Therapeutics, Inc. |
|
|
|
|
|
No Relationships to Disclose |
|
|
Employment - Perspective Therapeutics, Inc. |
Stock and Other Ownership Interests - Perspective Therapeutics, Inc. |
Travel, Accommodations, Expenses - Perspective Therapeutics, Inc. |
|
|
Employment - Mirati Therapeutics |
|
|
Employment - Perspective Therapeutics, Inc. |
Stock and Other Ownership Interests - Perspective Therapeutics, Inc. |
Travel, Accommodations, Expenses - Perspective Therapeutics, Inc. |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst) |
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst) |
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society |